BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
3.594
-0.076 (-2.07%)
Sep 8, 2025, 4:00 PM - Market closed

BioLineRx Statistics

Total Valuation

BioLineRx has a market cap or net worth of $16.08 million. The enterprise value is $388,301.

Market Cap16.08M
Enterprise Value 388,301

Important Dates

The last earnings date was Thursday, August 14, 2025, before market open.

Earnings Date Aug 14, 2025
Ex-Dividend Date n/a

Share Statistics

BioLineRx has 2.56 billion shares outstanding. The number of shares has increased by 65.34% in one year.

Current Share Class n/a
Shares Outstanding 2.56B
Shares Change (YoY) +65.34%
Shares Change (QoQ) +6.85%
Owned by Insiders (%) 0.17%
Owned by Institutions (%) 4.55%
Float 2.45B

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 0.93
Forward PS n/a
PB Ratio 0.80
P/TBV Ratio 1.66
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales 0.02
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.63.

Current Ratio 2.06
Quick Ratio 1.84
Debt / Equity 0.63
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -1.96

Financial Efficiency

Return on equity (ROE) is -45.94% and return on invested capital (ROIC) is -21.26%.

Return on Equity (ROE) -45.94%
Return on Assets (ROA) -15.36%
Return on Invested Capital (ROIC) -21.26%
Return on Capital Employed (ROCE) -47.69%
Revenue Per Employee $616,107
Profits Per Employee -$279,357
Employee Count28
Asset Turnover 0.32
Inventory Turnover 2.16

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -85.13% in the last 52 weeks. The beta is 0.89, so BioLineRx's price volatility has been lower than the market average.

Beta (5Y) 0.89
52-Week Price Change -85.13%
50-Day Moving Average 4.08
200-Day Moving Average 4.96
Relative Strength Index (RSI) 44.27
Average Volume (20 Days) 31,253

Short Selling Information

Short Interest 203,233
Short Previous Month 166,481
Short % of Shares Out 4.78%
Short % of Float n/a
Short Ratio (days to cover) 5.51

Income Statement

In the last 12 months, BioLineRx had revenue of $17.25 million and -$7.82 million in losses. Loss per share was -$0.00.

Revenue17.25M
Gross Profit 10.23M
Operating Income -13.25M
Pretax Income -49.15M
Net Income -7.82M
EBITDA -10.83M
EBIT -13.25M
Loss Per Share -$0.00
Full Income Statement

Balance Sheet

The company has $28.16 million in cash and $12.60 million in debt, giving a net cash position of $15.56 million or $0.01 per share.

Cash & Cash Equivalents 28.16M
Total Debt 12.60M
Net Cash 15.56M
Net Cash Per Share $0.01
Equity (Book Value) 20.07M
Book Value Per Share 0.01
Working Capital 16.38M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$21.20 million and capital expenditures $6,000, giving a free cash flow of -$21.20 million.

Operating Cash Flow -21.20M
Capital Expenditures 6,000
Free Cash Flow -21.20M
FCF Per Share -$0.01
Full Cash Flow Statement

Margins

Gross margin is 59.32%, with operating and profit margins of -76.81% and -45.34%.

Gross Margin 59.32%
Operating Margin -76.81%
Pretax Margin -45.34%
Profit Margin -45.34%
EBITDA Margin -62.78%
EBIT Margin -76.81%
FCF Margin n/a

Dividends & Yields

BioLineRx does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -65.34%
Shareholder Yield -65.34%
Earnings Yield -48.64%
FCF Yield -131.82%

Analyst Forecast

The average price target for BioLineRx is $19.00, which is 421.98% higher than the current price. The consensus rating is "Strong Buy".

Price Target $19.00
Price Target Difference 421.98%
Analyst Consensus Strong Buy
Analyst Count 2
Revenue Growth Forecast (5Y) n/a
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on January 30, 2025. It was a reverse split with a ratio of 1:40.

Last Split Date Jan 30, 2025
Split Type Reverse
Split Ratio 1:40

Scores

BioLineRx has an Altman Z-Score of -12.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -12.27
Piotroski F-Score 3